Terry W Copeland

US Patent:

52524779, Oct 12, 1993

Filed:

Jun 1, 1987

Appl. No.:

7/057183

Inventors:

Stephen Oroszlan - Potomac MD
Terry D. Copeland - Frederick MD

Assignee:

The United States of America as represented by the United States
Department of Health and Human Services - Bethesda MD

International Classification:

C12N 950
C12N 704
C12N 1584

US Classification:

435219

Abstract:

HIV protease necessary for the natural synthesis of HIV has been identified and sequenced. Rabbit antiserum against the C-terminal portion of HIV protease has been produced and used to isolate natural HIV protease and characterize its activity. In addition, a method for producing synthetic HIV protease having the correct stereospecific conformation and specific HIV proteolytic activity has been achieved.

US Patent:

51909693, Mar 2, 1993

Filed:

Dec 20, 1988

Appl. No.:

7/286977

Inventors:

Jeffrey J. Blumenstein - Germantown MD
Christopher J. Michejda - Potomac MD
Stephen Oroszlan - Potomac MD
Terry Copeland - Frederick MD

Assignee:

The United States of America as represented by the Secretary of the
Department of Health & Human Services - Washington DC

International Classification:

A61K 3140
A61K 31335

US Classification:

514422

Abstract:

The present invention is related to compounds, compositions and methods of treating viral infections. Compounds of the present invention have the following general formula: ##STR1## wherein R is selected from --CH. sub. 2 OH, --CO. sub. 2 R. sup. 2, --CONR. sup. 3 R. sup. 4, or COR. sup. 5, wherein R. sup. 2 is hydrogen or a lower alkyl group, R. sup. 3 and R. sup. 4 are each independently hydrogen or a lower alkyl group, R. sup. 5 is an amino acid residue bound via a terminal nitrogen or peptide having at least two amino acid residues; and wherein R. sup. 1 is C. sub. 5 -C. sub. 13 alkyl, aryl, aralkyl, aralkyl(lower alkyl) ether, or C. sub. 5 -C. sub. 13 alkyl (lower alkyl)ether.

US Patent:

61535893, Nov 28, 2000

Filed:

Dec 15, 1992

Appl. No.:

7/991251

Inventors:

Jeffrey J. Blumenstein - Germantown MD
Christopher J. Michejda - Potomac MD
Stephen Oroszlan - Potomac MD
Terry Copeland - Frederick MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 31336
A61K 3805
C07D30312
C07K 506

US Classification:

514 19

Abstract:

The present invention is related to compounds, compositions and methods of treating viral infections. Compounds of the present invention have the following general formula: ##STR1## wherein R is selected from --CH. sub. 2 OH, --CO. sub. 2 R. sup. 2, --CONR. sup. 3 R. sup. 4, or COR. sup. 5, wherein R. sup. 2 is hydrogen or a lower alkyl group, R. sup. 3 and R. sup. 4 are each independently hydrogen or a lower alkyl group, R. sup. 5 is an amino acid residue bound via a terminal nitrogen or peptide having at least two amino acid residues; and wherein R. sup. 1 is C. sub. 5 -C. sub. 13 alkyl, aryl, aralkyl, aralkyl(lower alkyl)ether, or C. sub. 5 -C. sub. 13 alkyl(lower alkyl)ether.

US Patent:

53546830, Oct 11, 1994

Filed:

Jul 30, 1993

Appl. No.:

8/100703

Inventors:

Stephen Oroszlan - Potomac MD
Terry D. Copeland - Frederick MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C12N 950
C12N 704

US Classification:

435219

Abstract:

HIV protease necessary for the natural synthesis of HIV has been identified and sequenced. This antibody cross reacts with the protease of HIV-2. In addition, a method for producing synthetic HIV-1 and HIV-2 protease having the correct stereospecific conformation and specific HIV proteolytic activity has been achieved. Assays for the synthetic proteases using synthetic peptide substrates have been developed.